JOHNSON & JOHNSON (JNJ): 10-K filed February 13, 2025

AI analysis of the 10-K that JOHNSON & JOHNSON filed with the U.S. SEC on February 13, 2025, grounded in the primary-source EDGAR filing.

• Talc/Asbestos Litigation: Unresolved material contingent liability with ongoing cases and settlements poses significant financial and reputational risks requiring sustained capital allocation and potential future charges.

• Patent Cliff Exposure: Multiple key pharmaceutical products approaching exclusivity loss will create predictable revenue headwinds and margin compression, threatening near-term growth trajectory.

• Regulatory Pricing Headwinds: Intensifying global pricing pressure from government controls and reimbursement restrictions is eroding pricing power and limiting margin expansion opportunities across markets.

• Neutral Management Tone: Factual risk disclosure with limited forward guidance suggests cautious outlook; management appears focused on damage control rather than growth optimization.

• Investor Implication: Fundamental headwinds to revenue and margins are structural rather than cyclical, requiring portfolio transition strategy and realistic expectations for near-to-medium term performance.

Filing analysis — key questions

Answers are generated from this SEC filing and StockHuntr's analysis. Not investment advice.

What does JOHNSON & JOHNSON (JNJ)'s 10-K filed February 13, 2025 say?

Company Overview: Johnson & Johnson is a pharmaceutical preparations company incorporated in New Jersey, with headquarters in New Brunswick, NJ, operating across multiple business segments in life sciences Filing Period: Annual report for fiscal year ended December 29, 2024, filed on February 13, 2025, covering the complete 2024 fiscal year Financial Structure: The filing includes comprehensive…

Is JNJ's 10-K bullish or bearish?

Our analysis rates this filing CAUTIOUS. Johnson & Johnson presents an elevated but manageable risk profile typical of large-cap pharmaceutical companies. The concern level of 6.2 reflects the material talc litigation exposure (severity 7) combined with structural industry headwinds (patent cliffs,…

How concerning is JNJ's latest 10-K?

Concern level: HIGH (6.2/10). Key factors: One high-severity risk identified: Talc/asbestos litigation (severity 7/10) representing material contingent liability with ongoing cases and no clear resolution path; Structural headwinds from pharmaceutical patent expirations creating predictable revenue compression and margin pressure in core business; Intensifying regulatory and reimbursement…

What are the main risks flagged in JNJ's 10-K?

Notable risk changes: Talc/Asbestos litigation remains a material contingent liability with ongoing cases and settlements; represents significant financial and reputational exposure that has not been resolved; Pharmaceutical patent expirations creating predictable revenue headwinds; multiple key products losing exclusivity will compress margins and growth rates; Regulatory pricing pressure intensifying globally with…

About this analysis

Primary source:
View this 10-K on SEC EDGAR
Additional data:
Yahoo Finance (market data)
Method:
StockHuntr analyzes filings with AI — see our methodology.
Analysis as of:
February 13, 2025
Published by:
StockHuntr

For research and education only. Nothing here is investment advice.

📄

Fetching Filing from SEC

Downloading filing HTML from SEC.gov...

15% Complete
1
Fetch filing from SEC
2
Parse document sections
3
Fetch prior filing
4
Analyze risk factors
5
Analyze management sentiment
6
Extract financial metrics
7
Compare to analyst consensus
8
Run ML prediction model
9
Finalize analysis

Note: Analysis typically takes 30-60 seconds. We're fetching real SEC filing data and running AI analysis on the actual content.